Bicara Therapeutics Inc. Common Stock (BCAX) Stock Overview
Explore Bicara Therapeutics Inc. Common Stock’s financial performance, market position, analyst ratings, and future outlook.
Bicara Therapeutics Inc. Common Stock (BCAX)
Key Financials
Key Financials
Market Cap
1.4B
P/E Ratio
-7.11
EPS (TTM)
$-3.10
ROE
-0.41%
BCAX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Bicara Therapeutics Inc. Common Stock's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of BCAX on the NASDAQ shows an RSI of 37.44, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $32.61 for the NASDAQ listing.
Key metrics behind Bicara Therapeutics Inc. Common Stock's NASDAQ-traded stock include a P/E ratio of -7.11 and a market capitalization of 1.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BCAX on the NASDAQ.